Zydus Lifesciences Management
Management criteria checks 2/4
Zydus Lifesciences' CEO is Sharvil Patel, appointed in Apr 2017, has a tenure of 7.08 years. total yearly compensation is ₹262.50M, comprised of 68.6% salary and 31.4% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth ₹14.10M. The average tenure of the management team and the board of directors is 6 years and 9 years respectively.
Key information
Sharvil Patel
Chief executive officer
₹262.5m
Total compensation
| CEO salary percentage | 68.6% |
| CEO tenure | 7.1yrs |
| CEO ownership | 0.001% |
| Management average tenure | 6yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18
Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate
Aug 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 25Zydus Lifesciences (NSE:ZYDUSLIFE) Has Announced That Its Dividend Will Be Reduced To ₹2.50
Jul 10Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Jul 07Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 23Zydus Lifesciences (NSE:ZYDUSLIFE) Is Reducing Its Dividend To ₹2.50
Jun 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Reduced To ₹2.50
May 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹30b |
| Sep 30 2023 | n/a | n/a | ₹28b |
| Jun 30 2023 | n/a | n/a | ₹25b |
| Mar 31 2023 | ₹263m | ₹180m | ₹20b |
| Dec 31 2022 | n/a | n/a | ₹21b |
| Sep 30 2022 | n/a | n/a | ₹20b |
| Jun 30 2022 | n/a | n/a | ₹22b |
| Mar 31 2022 | ₹200m | ₹180m | ₹22b |
| Dec 31 2021 | n/a | n/a | ₹23b |
| Sep 30 2021 | n/a | n/a | ₹23b |
| Jun 30 2021 | n/a | n/a | ₹23b |
| Mar 31 2021 | ₹263m | ₹180m | ₹22b |
| Dec 31 2020 | n/a | n/a | ₹18b |
| Sep 30 2020 | n/a | n/a | ₹17b |
| Jun 30 2020 | n/a | n/a | ₹13b |
| Mar 31 2020 | ₹250m | ₹247m | ₹12b |
| Dec 31 2019 | n/a | n/a | ₹12b |
| Sep 30 2019 | n/a | n/a | ₹14b |
| Jun 30 2019 | n/a | n/a | ₹17b |
| Mar 31 2019 | ₹250m | ₹248m | ₹18b |
| Dec 31 2018 | n/a | n/a | ₹20b |
| Sep 30 2018 | n/a | n/a | ₹20b |
| Jun 30 2018 | n/a | n/a | ₹21b |
| Mar 31 2018 | ₹250m | ₹248m | ₹18b |
Compensation vs Market: Sharvil's total compensation ($USD3.14M) is above average for companies of similar size in the Indian market ($USD941.33K).
Compensation vs Earnings: Sharvil's compensation has increased by more than 20% in the past year.
CEO
Sharvil Patel (44 yo)
7.1yrs
Tenure
₹262,500,000
Compensation
Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 7.1yrs | ₹262.50m | 0.0015% ₹ 14.1m | |
| COO & Executive Director | 6.8yrs | ₹120.00m | 0.035% ₹ 332.0m | |
| President & CEO of America | less than a year | no data | no data | |
| Chief Financial Officer | no data | ₹54.31m | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Company Secretary & Compliance Officer | 5.3yrs | ₹2.09m | no data |
6.0yrs
Average Tenure
Experienced Management: ZYDUSLIFE's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 26.8yrs | ₹262.50m | 0.0015% ₹ 14.1m | |
| COO & Executive Director | 6.8yrs | ₹120.00m | 0.035% ₹ 332.0m | |
| Non-Executive Chairman | 29yrs | ₹1.60m | 74.98% ₹ 719.4b | |
| Independent Director | 8yrs | ₹4.60m | no data | |
| Non-Executive Non-Independent Director | 26.8yrs | ₹4.80m | 0.0012% ₹ 11.1m | |
| Independent Director | 5.4yrs | ₹4.60m | no data | |
| Non-Executive Independent Director | 10yrs | ₹4.50m | no data | |
| Non-Executive Independent Director | 13yrs | ₹4.30m | 0.046% ₹ 444.5m | |
| Independent Director | 1.5yrs | ₹1.20m | no data | |
| Independent Director | 1.5yrs | ₹1.20m | no data |
9.0yrs
Average Tenure
68yo
Average Age
Experienced Board: ZYDUSLIFE's board of directors are considered experienced (9 years average tenure).